Question 1

What does Assyro support for MFDS submissions?

Accepted Answer

Assyro supports submissions to the Ministry of Food and Drug Safety (MFDS), Republic of Korea. Your Korean filing runs in the same workspace as your FDA, Health Canada, and EMA submissions. Book a demo to walk through your Korean program.

Question 2

What is the MFDS?

Accepted Answer

The Ministry of Food and Drug Safety (MFDS) is the national regulator of the Republic of Korea for pharmaceuticals, biologics, medical devices, and food. It is a regulatory member of the International Council for Harmonisation (ICH).

Question 3

How is a Korean eCTD submission structured?

Accepted Answer

Like other ICH regions, Korea uses a regional Module 1 for administrative and product information, while Modules 2 to 5 follow the ICH Common Technical Document (CTD) structure.

Question 4

How does Korea's MFDS approval process compare to FDA's?

Accepted Answer

In broad terms it follows the same two stages. A sponsor first needs MFDS approval of the clinical trial plan, often called an IND approval, along with ethics committee approval, before a trial starts in Korea. To market the product, the sponsor then applies to MFDS for product approval, the counterpart of an FDA NDA. Timelines, data requirements, and local steps differ, so confirm the current requirements for your product with MFDS guidance or a Korean regulatory partner.

Question 5

Is MFDS clinical trial approval the same as an FDA IND?

Accepted Answer

They serve the same purpose but work differently. Under an FDA IND, a trial may generally proceed 30 days after submission unless FDA places it on clinical hold. In Korea, the sponsor waits for MFDS to approve the clinical trial plan before the trial begins.

Question 6

How are biologics reviewed in Korea?

Accepted Answer

MFDS reviews biological products such as vaccines, blood products, and cell and gene therapies under requirements specific to biologics, separate from chemical drugs. This is broadly comparable to FDA's split between NDAs for drugs and BLAs for biologics. Advanced therapies in Korea are also subject to dedicated legislation on advanced regenerative bio products.

Question 7

Can we manage MFDS, FDA, Health Canada, and EMA submissions in one place?

Accepted Answer

Yes. Your Korean submission sits in the same Assyro workspace as your FDA, Health Canada, and EMA submissions for the same program, so one team sees every filing.

Question 8

Does Assyro decide what we file with MFDS?

Accepted Answer

No. AI drafts, checks, and triages the work. Your regulatory professionals review it and decide what is submitted to the MFDS.

Question 9

How do we start an MFDS submission with Assyro?

Accepted Answer

Book a demo with your program details: the product, the submission type, and your target filing date. We walk through how Assyro handles your Korean submission.

Korea MFDS eCTD Submissions, Coordinated in One Workspace

MFDS Filing Workflow

Korea in the Same Workspace

Clear Owners for Every Korean Task

Status Without the Rebuild

Decisions You Can Find Again

MFDS Filing Controls and Capacity

Maintain Audit-Ready MFDS Records

Manage More MFDS Programs With the Same Team Size

Guides for your next decision

Questions About MFDS Submission Software

See Your Korean Submission in Assyro.